

3/1/2022

Medicare Part D Formulary Change

The product changes noted below will be implemented on the Medicare Part D Plan:

New Added Products: **Effective 3/1/2022**

Drug	Reason	Cost sharing**	Restrictions***
BESREMI 500 MCG/ML SUBCUTANEOUS SYRINGE	New Drug	Tier 5	PA LA
DUPIXENT 100 MG/0.67 ML SUBCUTANEOUS SYRINGE	New Drug	Tier 5	PA QL
EPCLUSA 150 MG-37.5 MG ORAL PELLETS IN PACKET	New Drug	Tier 5	PA QL
EPCLUSA 200 MG-50 MG ORAL PELLETS IN PACKET	New Drug	Tier 5	PA QL
EPRONTIA 25 MG/ML ORAL SOLUTION	New Drug	Tier 4	PA
everolimus (immunosuppressive) 1 mg tablet	New Drug	Tier 5	PA
EXKIVITY 40 MG CAPSULE	New Drug	Tier 5	PA QL LA
SCEMBLIX 20 MG TABLET	New Drug	Tier 5	PA QL
SCEMBLIX 40 MG TABLET	New Drug	Tier 5	PA QL
TICOVAC 2.4 MCG/0.5 ML INTRAMUSCULAR SYRINGE	New Drug	Tier 3	
TRUDHESA 0.725 MG/PUMP ACT. (4 MG/ML) NASAL SPRAY	New Drug	Tier 5	ST QL

Future Removed Products: **Effective 3/1/2022**

Drug	Reason	Alternative*
zarah 3 mg-0.03 mg tablet	Removed from Formulary	Please contact your doctor.

Cost Sharing Tier Changes: **There were no cost sharing tier changes this month.**

**Consult your Medical provider for changes or recommendations to your medical care and prescription therapy

**Please consult the plan benefit design for copay/coinsurance amounts

***Indicates a restriction of Step Therapy, Prior Authorization or Quantity Limits may exist [LA] = Limited Access, [PA] = Prior Authorization, [QL] = Quantity Limit, [ST] = Step Therapy PRF-C6T"